CI

At a glance

ClinicalIndex Comparison Record
Phase 2Not Yet Recruiting· 58 target
Drug / intervention
SHR-1501+SHR-2005drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06588179
NCT06588179Phase 2Not Yet Recruiting
CompareCT.gov

Phase Ib/II Clinical Study of SHR-1501 Combined With SHR-2005 in the Treatment of Patients With High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt

Fudan University·interventional·Posted Sep 19, 2024·Updated Sep 19, 2024

In Brief

A Phase 2 clinical trial evaluating SHR-1501+SHR-2005 for NMIBC. Not yet recruiting, targeting 58 participants across 1 site.

Detailed Summary

This is a single-center, single-arm, phase Ib/II study, aimed at assessing the safety and efficacy of SHR-1501 in combination with SHR-2005 as treatment for patients with high-risk non-muscle invasive bladder cancer (HR NMIBC) which is not completely resectable by transurethral resection of bladder tumor (TURBt).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNMIBC
CountriesChina
Collaborators--

Timeline

Phase 2Not Yet Recruiting
202520262027
First PostedSep 19, 2024
Enrollment StartOct 1, 2024
Primary CompletionOct 1, 2027
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 1.8 years agoPrimary completion in 1.3 years

Interventions

SHR-1501+SHR-2005drug

SHR-1501, instillation；SHR-2005, instillation